Therapeutic monoclonal antibodies in combination with pomalidomide can overcome refractoriness to both agents in multiple myeloma: A case ‐based approach
Abstract
In multiple myeloma (MM), the synergy between immunomodulatory drugs (IMiDs) and monoclonal antibodies (MABs) has been demonstrated in several pivotal trials. However, disease refractory to either class of compounds remains a major therapeutic challenge. We here report on 3 heavily pretreated MM patients who were refractory to pomalidomide as well as to MABs against CD38 (daratumumab) or CD20 (rituximab), respectively, but who responded to retreatment with the same agents in combination. Responses were durable with PFS of 7, 10 (ongoing), and 30 months from initiation of combination treatment. The combination of ...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Marc ‐Andrea Baertsch, Michael Hundemer, Jens Hillengass, Hartmut Goldschmidt, Marc S. Raab Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B ‐cell lymphoma of the mucosa‐associated lymphoid tissue (MALT lymphoma)
Abstract
Lenalidomide is an active agent for the treatment of MALT lymphoma. Recently, high expression levels of cereblon (CRBN) and MUM1 have been associated with better response rates in multiple myeloma treated with lenalidomide. However, there are no data on CRBN and MUM1 expression in MALT lymphoma. In the current study, we have systematically investigated a potential correlation of CRBN/MUM1 immunohistochemical expression and response to lenalidomide‐based therapy in a series of 46 patients with MALT lymphoma treated at the Medical University Vienna 2009 to 2014. In total, 28% (13/46) of biopsy specimens derived fr...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Barbara Kiesewetter, Ingrid Simonitsch ‐Klupp, Christoph Kornauth, Werner Dolak, Julius Lukas, Marius E. Mayerhoefer, Markus Raderer Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Feasibility of myeloablative allogeneic hematopoietic cell transplantation from unrelated donors for patients with relapsed or refractory multiple myeloma
(Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Sumito Shingaki, Nobuhiro Tsukada, Tadao Ishida, Kenshi Suzuki Tags: LETTER TO THE EDITOR Source Type: research
IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma
Abstract
Single nucleotide polymorphisms (SNPs) in interleukin 17 (IL17A) and IL‐23 receptor (IL23R) are involved in the pathogenesis of many cancers and autoimmune diseases. We investigated the influence of IL17A and IL23R SNPs on the risk of developing multiple myeloma (MM) and its clinical features. We obtained genomic DNA from 120 patients with MM and 201 healthy controls and detected IL17A −197 G/A (rs2275913) and IL23R H3Q (rs1884444) genotypes using the polymerase chain reaction‐restriction fragment length polymorphism method. There were no significant differences in the genotype and allele frequencies of IL17...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Tetsuhiro Kasamatsu, Mari Kimoto, Noriyuki Takahashi, Yusuke Minato, Nanami Gotoh, Makiko Takizawa, Morio Matsumoto, Morio Sawamura, Akihiko Yokohama, Hiroshi Handa, Norifumi Tsukamoto, Takayuki Saitoh, Hirokazu Murakami Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
FarmaREL: An Italian pharmacovigilance project to monitor and evaluate adverse drug reactions in haematologic patients
Abstract
Adverse drug reactions (ADRs) reduce patients' quality of life, increase mortality and morbidity, and have a negative economic impact on healthcare systems. Nevertheless, the importance of ADR reporting is often underestimated. The project “FarmaREL” has been developed to monitor and evaluate ADRs in haematological patients and to increase pharmacovigilance culture among haematology specialists. In 13 haematology units, based in Lombardy, Italy, a dedicated specialist with the task of encouraging ADRs reporting and sensitizing healthcare professionals to pharmacovigilance has been assigned. The ADRs occurring ...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Nicola S. Fracchiolla, Silvia Artuso, Agostino Cortelezzi, Anna M. Pelizzari, Paola Tozzi, Maurizio Bonfichi, Federica Bocchio, Livio Gargantini, Elisa De Rosa, Giuseppe D. Vighi, Lucia Prestini, Simona Sammassimo, Niccol ò Frungillo, Maria C. Pasquini, Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Spectrum and immunophenotyping of 653 patients with B ‐cell chronic lymphoproliferative disorders in China: A single‐centre analysis
Abstract
The incidence of B‐cell chronic lymphoproliferative disorders (B‐CLPDs) is significantly lower in China than that in western countries. There have been studies involving small cohorts with conflicting results regarding the spectrum of B‐CLPDs in China, and the types and immunophenotyping of B‐CLPDs in China remain largely unexplored. We conducted a retrospective analysis of 653 cases of B‐CLPDs seen in our centre from 2011 to 2015. Four‐colour flow cytometry was used to determine the expression of each immunological marker, and the diagnostic values of the immunological markers were also investigated. ...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Yi Miao, Lei Cao, Qian Sun, Xiao ‐Tong Li, Yan Wang, Chun Qiao, Li Wang, Rong Wang, Hai‐Rong Qiu, Wei Xu, Jian‐Yong Li, Yu‐Jie Wu, Lei Fan Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Epstein ‐Barr virus positivity is associated with angiogenesis in, and poorer survival of, patients receiving standard treatment for classical Hodgkin's lymphoma
Abstract
Epstein‐Barr virus (EBV) is a significant contributor to the development of classical Hodgkin's lymphoma (cHL). Recent studies have documented associations between angiogenesis and EBV‐associated malignancies. No study has yet examined the associations among, and prognostic implications of, EBV infection, vascular endothelial growth factor (VEGF) expression, and microvessel density (MVD) in cHL patients. Diagnostic tissues from 135 cHL patients treated with adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) were retrospectively evaluated by in situ hybridization of EBV‐encoded small RNA (EBER) and im...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Young Wha Koh, Jae ‐Ho Han, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Mean platelet volume predicts prognosis in patients with diffuse large B ‐cell lymphoma
Abstract
To determine the prognostic value of baseline mean platelet volume (MPV) in diffuse large B‐cell lymphoma (DLBCL) patients. We retrospectively analyzed 161 DLBCL patients who received R‐CHOP chemotherapy. The associations between MPV and clinicopathological factors were assessed. A low MPV (MPV ≤ 9.1 fl, cut‐off was calculated by receiver operating characteristics) was associated with any other clinicopathological factors. Patients with MPV ≤ 9.1 fl experienced a shorter progression‐free survival (PFS) (2‐year PFS rate, 60.6% vs 84.0%, P = 0.003) and overall survival (OS) (2‐year OS rate, 7...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Shujuan Zhou, Yongyong Ma, Yifen Shi, Liyuan Tang, Zhouyi Zheng, Fang Fang, Jianhua Feng, Yu Zhang, Lan Sun, Yi Chen, Bin Liang, Songfu Jiang, Zhijian Shen, Kang Yu, Siqian Wang Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Microenvironment modulation and enhancement of antilymphoma therapy by the heparanase inhibitor roneparstat
(Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Anna Rossini, Franco Zunino, Giusi Ruggiero, Michelandrea De Cesare, Denis Cominetti, Monica Tortoreto, Cinzia Lanzi, Giuliana Cassinelli, Roberta Zappasodi, Claudio Tripodo, Alessandro Gulino, Nadia Zaffaroni, Massimo Di Nicola Tags: LETTER TO THE EDITOR Source Type: research
Nodular lymphocyte predominant Hodgkin's lymphoma in daily practice: A multicenter experience
In this study, we aimed to investigate the clinical features and therapeutic outcomes of patients with NLPHL who were diagnosed at different institutes in Turkey.
We retrospectively reviewed the records of the patients diagnosed with NLPHL. Adult patients who were diagnosed after 2005 with histological confirmation were selected for the study. Forty‐three patients were included in the study. Median age of patients was 37.5 years (18‐70) at the time of diagnosis. About 60.5% patients were diagnosed as stage I and II NLPHL, and remaining 39.5% had stage III and IV disease. Median follow‐up was 46 months. During follo...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Aliihsan Gemici, Ismet Aydogdu, Hatice Terzi, Mehmet Sencan, Alma Aslan, Ali Hakan Kaya, Mehmet Sinan Dal, Meltem Olga Akay, Mehmet Hilmi Dogu, Orhan Ayyildiz, Fahri Sahin, Gulsum Akgun Cagliyan, Mehmet Yilmaz, Zafer Gokgoz, Yusuf Bilen, Cengiz Demir, Omu Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Epstein ‐Barr virus‐negative extranodal “true” natural killer‐cell lymphoma harbouring a KDM6A mutation
Abstract
Extranodal natural killer (NK)/T‐cell lymphoma, nasal type (ENKTL) is an extranodal aggressive T or NK‐cell lymphoma that is characteristically associated with Epstein‐Barr virus (EBV) infection and cytotoxic tissue‐destructive features. Although ENKTL is described as a distinct entity according to the 2008 WHO classification, a considerable complexity is associated with the differential diagnosis of other T‐cell lymphomas with respect to tumour cell origins, locations, and the presence of EBV infection, as well as molecular and cytogenetic abnormalities. Here, we report a rare case of EBV‐negative ENK...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Naoko Tsuyama, Reimi Asaka, Akito Dobashi, Satoko Baba, Yuko Mishima, Kyoko Ueda, Masahiko Oguchi, Hideki Tsuji, Kiyohiko Hatake, Kengo Takeuchi Tags: CASE REPORT Source Type: research
Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice
In conclusion, FVD showed efficacy in a heavily pretreated, high‐risk multiple myeloma population with a high degree of patients refractory to novel agents including PIs. (Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Marc ‐Andrea Baertsch, Jens Hillengass, Joanna Blocka, Stefan Schönland, Ute Hegenbart, Hartmut Goldschmidt, Marc S. Raab Tags: ORIGINAL RESEARCH ARTICLE Source Type: research
Ibrutinib ‐induced rapid response in chemotherapy‐refractory Richter's syndrome
(Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Angela Fischer, Sara Bastian, Sergio Cogliatti, Ulrich Mey, Jenny Saub, Urs Schanz, Barbara Padberg, Karin Hohloch Tags: LETTER TO THE EDITOR Source Type: research
Intensive induction chemotherapy vs hypomethylating agent –based regimen in patients aged ≥70 years with newly diagnosed acute myeloid leukemia
(Source: Hematological Oncology)
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: Matthew J. Lim, Aya Agha, Annie Im, Anastasios Raptis, Jing Z. Hou, Michael Boyiadzis, Alison R. Sehgal, Robert L. Redner, Kathleen Dorritie, Stanley S. Marks, Mounzer E. Agha, Seah H. Lim Tags: LETTER TO THE EDITOR Source Type: research
Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant
Abstract
Cytomegalovirus (CMV) infection in clinical settings other than the allogeneic transplant represents a poorly explored issue. Thus, we performed a comprehensive review of the medical literature about CMV infection in patients undergoing autologous hematopoietic stem cell transplant and in other nontransplant‐related hematologic patients. In autologous hematopoietic stem cell transplant, a CMV reactivation is reported to occur in up to 41% of CMV seropositive patients, when a prospective monitoring of antigenemia and/or viremia by polymerase chain reaction was adopted. However, more contained frequencies, up to 1...
Source: Hematological Oncology - June 1, 2017 Category: Hematology Authors: F. Marchesi, F. Pimpinelli, F. Ensoli, A. Mengarelli Tags: REVIEW Source Type: research
